<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: Sickle cell variant in the hemoglobin beta locus (&lt;i&gt;HBB&lt;/i&gt;)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: Sickle cell variant in the hemoglobin beta locus (<i>HBB</i>)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: Sickle cell variant in the hemoglobin beta locus (<i>HBB</i>)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elliott P Vichinsky, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R DeBaun, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3088948971"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph discusses interpretation and possible interventions based on a genetic test result that reveals the sickle cell variant in the hemoglobin beta locus (<em>HBB</em>, also called beta globin gene). It does not discuss indications for testing and is not intended to replace clinical judgment in the decision to test or the care of the individual who was tested. These subjects are discussed separately [<a href="#rid1">1</a>]. (See <a class="local">'UpToDate topics'</a> below.)</p><p class="headingAnchor" id="H3530507989"><span class="h1">HOW TO READ THE REPORT</span><span class="headingEndMark"> — </span>Obtain a hard copy or digital report rather than a verbal statement. Confirm the correct person (not a relative) was tested. If the sickle cell variant is identified, determine if the individual is heterozygous or homozygous and whether other variants were identified.</p><p>Testing can be done using targeted genetic testing for the sickle cell variant or full sequencing of the hemoglobin beta locus (<em>HBB</em>) gene. The latter would allow other variants in <em>HBB</em> to be detected, since variants in <em>HBB</em> other than the sickle cell variant (beta thalassemia variants, hemoglobin C) can have important implications for the tested individual. Additional information may be inferred from protein-based hemoglobin analysis (high performance liquid chromatography [HPLC] or immunoelectrophoresis [IEF]). </p><p>Genetic testing should be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. If testing was not done in a CLIA-certified laboratory or was done by direct-to-consumer testing or for a research study and the results would impact clinical care (positive result, negative result in an individual with a positive personal or family history), confirm the result by repeat genetic testing or hemoglobin analysis in a CLIA-certified laboratory. (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing"</a>.)</p><p>The sickle prep (SickleDex) or solubility test alone are <strong>not</strong> sufficient to confirm or exclude the diagnosis of sickle cell trait or sickle cell disease.</p><p>Positive testing for the sickle cell variant may be reported as:</p><p class="bulletIndent1"><span class="glyph">●</span>Sickle cell variant; hemoglobin S (Hb S)</p><p class="bulletIndent1"><span class="glyph">●</span>c.20A&gt;T (DNA sequence change)</p><p class="bulletIndent1"><span class="glyph">●</span>p.Glu7Val (protein sequence change, previously called pGlu6Val using an earlier amino acid numbering system)</p><p></p><p>The tables provide caveats related to genetic testing  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>) and a glossary  (<a class="graphic graphic_table graphicRef122429" href="/d/graphic/122429.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1201211166"><span class="h1">DISEASE ASSOCIATIONS</span><span class="headingEndMark"> — </span>The sickle cell variant is a point mutation in the hemoglobin beta locus (<em>HBB</em>). It introduces a single amino acid substitution that leads to a physical change in the beta globin chains of the hemoglobin molecule, producing hemoglobin S (Hb S) [<a href="#rid2">2</a>]. </p><p>Red blood cells with Hb S can undergo sickling, but this generally will not occur unless &gt;50 percent of the cell's hemoglobin is Hb S. The inheritance pattern is autosomal recessive  (<a class="graphic graphic_table graphicRef122429" href="/d/graphic/122429.html" rel="external">table 2</a>). Other physiologic changes that contribute to sickling in certain organs are discussed separately. (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease"</a>.)</p><p>Whether an individual with the sickle cell variant will have sickle cell trait or sickle cell disease depends on the status of the <em>HBB</em> gene inherited from the other parent. This is summarized in the table  (<a class="graphic graphic_table graphicRef122837" href="/d/graphic/122837.html" rel="external">table 3</a>) and illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef123053" href="/d/graphic/123053.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell trait</strong> – When an individual is heterozygous for the sickle cell variant and the other <em>HBB</em> gene lacks a hemoglobinopathy variant, the individual has sickle cell trait. They are essentially an unaffected carrier, although there are some clinical implications that require counseling. (See <a class="local">'People with sickle cell trait'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell disease</strong> – When an individual has the sickle cell variant in combination with another disease-associated <em>HBB</em> variant, they have sickle cell disease, which carries a risk of serious end-organ damage. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Homozygous Hb S</strong> – Individuals with homozygosity (Hb SS) have sickle cell anemia (a form of sickle cell disease), often identified by newborn screening or testing. The affected child usually develops clinical findings during infancy, such as anemia and vaso-occlusive pain (dactylitis) in the hands. They are at risk for severe end-organ damage, including stroke, and they should receive comprehensive care from a hematologist or other expert in order to reduce these risks. (See <a class="local">'People with sickle cell disease'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Compound heterozygosity</strong> – Individuals with heterozygosity for the sickle cell variant and another disease-associated <em>HBB</em> variant (Hb C, beta thalassemia) also have sickle cell disease. Some will present similarly to individuals who are homozygous for Hb SS; others may have a milder course and may be unaware of their diagnosis. However, they are at risk for serious end-organ damage and should receive comprehensive care by a hematologist or other expert to reduce these risks. (See <a class="local">'People with sickle cell disease'</a> below.)</p><p></p><p>An individual with the sickle cell variant may also have variants affecting the <strong>alpha</strong> globin loci (<em>HBA1</em> or <em>HBA2</em>), which may be reported as alpha thalassemia trait or hemoglobin H disease. Unlike a second <em>HBB</em> variant, a variant affecting alpha globin generally reduces the severity of the sickle cell variant. Individuals with sickle cell trait and an alpha thalassemia variant have sickle cell trait, not sickle cell disease. </p><p>The clinical implications for the patient and family members should be discussed with a hematologist, genetic counselor, or other expert. (See <a class="local">'Considerations for relatives'</a> below and <a class="local">'Resources'</a> below.)</p><p class="headingAnchor" id="H3960670718"><span class="h1">PEOPLE WITH SICKLE CELL TRAIT</span><span class="headingEndMark"> — </span>Sickle cell trait refers to heterozygosity for the sickle cell variant (hemoglobin S [Hb S]) in combination with a normal beta globin gene on the other allele  (<a class="graphic graphic_algorithm graphicRef123053" href="/d/graphic/123053.html" rel="external">algorithm 1</a>). (See <a class="local">'Disease associations'</a> above.)</p><p>Sickle cell trait is a benign carrier condition. It affects millions of individuals, the vast majority of whom are asymptomatic and may be unaware they have sickle cell trait. Their lifespan is normal, and they do not have a disease. </p><p>Individuals with sickle cell trait should be aware of a few rare medical complications  (<a class="graphic graphic_table graphicRef122837" href="/d/graphic/122837.html" rel="external">table 3</a>) [<a href="#rid3">3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of complications of dehydration. Heat-induced and exercise-induced injury and death can be mitigated with universal precautions (proper conditioning and adequate hydration) rather than altering participation for physical activities or training [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Rhabdomyolysis and sudden death during strenuous physical activity'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of complications associated with high altitudes, airplane travel, or increased atmospheric pressure (scuba diving). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of urologic and kidney disease (urinary tract infection, chronic kidney disease). Hematuria, even if transient, should be evaluated due to an increased risk of a rare cancer. (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Urologic and kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyposthenuria (reduced urinary concentrating ability) may lead to bedwetting, polyuria/nocturia, or dehydration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of splenic infarction. (See  <a class="medical medical_review" href="/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Focal splenic lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Slightly increased risk of venous thromboembolism (VTE), especially pulmonary embolism. This is important for education but should not limit access to contraceptives or otherwise alter management. (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Reproductive issues'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complications of traumatic hyphema (blood in the anterior chamber of the eye), warranting hospital admission and ophthalmologist consultation. (See  <a class="medical medical_review" href="/d/html/95661.html" rel="external">"Traumatic hyphema: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underestimation of glycosylated hemoglobin (HbA1c; A1C) for a given serum glucose level. Sickle cell trait does not confer an increased risk for diabetes. If screening or monitoring of diabetes is indicated, glucose measurements, which are not affected by the sickle cell variant, may be used instead of HbA1c. (See  <a class="medical medical_review" href="/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'A1C'</a> and  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Glycemic management'</a> and  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Inadequate evidence or conflicting results on the risk of hypertension, diabetes, heart disease, or stroke'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Slightly increased risk of renal medullary carcinoma, a rare type of kidney cancer. (See  <a class="medical medical_review" href="/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney", section on 'Renal medullary carcinoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possibility of sickle cell trait or disease in relatives. (See <a class="local">'Considerations for relatives'</a> below.)</p><p></p><p>Counseling may require additional visits or referral to a hematologist or genetic counselor. (See <a class="local">'Resources'</a> below.)</p><p class="headingAnchor" id="H3200805406"><span class="h1">PEOPLE WITH SICKLE CELL DISEASE</span><span class="headingEndMark"> — </span>Sickle cell disease refers to homozygosity for the sickle cell variant (Hb SS) or compound heterozygosity for the sickle cell variant with another beta globin variant  (<a class="graphic graphic_algorithm graphicRef123053" href="/d/graphic/123053.html" rel="external">algorithm 1</a>). Some people such as those with Hb SS or sickle-beta<sup>0</sup>-thalassemia may have obvious clinical findings, whereas others may be unaware of their status (eg, sickle cell variant in combination with hemoglobin C [Hb SC disease] or mild beta thalassemia). (See  <a class="medical medical_review" href="/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E"</a> and  <a class="medical medical_review" href="/d/html/7115.html" rel="external">"Overview of compound sickle cell syndromes"</a>.)</p><p>If the diagnosis is in question, the individual should have a hemoglobin analysis. (See  <a class="medical medical_review" href="/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders"</a> and  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Protein chemistry methods'</a>.)</p><p>All individuals with sickle cell disease require multidisciplinary comprehensive care  (<a class="graphic graphic_table graphicRef122837" href="/d/graphic/122837.html" rel="external">table 3</a>) to maximize life expectancy and reduce the risk of complications involving the kidney, joints, eye, and pregnancy, among others [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/5937.html" rel="external">"Evaluation and management of fever in children and adults with sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H2375423649"><span class="h1">CONSIDERATIONS FOR RELATIVES</span></p><p class="headingAnchor" id="H2442636425"><span class="h2">Preconception counseling</span><span class="headingEndMark"> — </span>Preconception genetic counseling and partner testing is appropriate for all individuals who carry the sickle cell variant and are considering childbearing. </p><p>The sickle cell variant can occur in all ethnic and racial groups, and any partner may have an undetected asymptomatic beta globin variant. Partner testing should include the sickle cell variant, beta thalassemia variants, hemoglobin C, and other beta globin variants. This is essential to determine the risk of sickle cell disease in the child(ren). Certain variants are found more frequently in specific populations, but the presence or absence of a hemoglobinopathy variant <strong>cannot</strong> be inferred from racial or ethnic background. (See  <a class="medical medical_review" href="/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p>Screening before pregnancy allows the provider to review diagnostic approaches and reproductive technologies to help couples with pregnancy decisions. Some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). (See  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.)</p><p class="headingAnchor" id="H1152100308"><span class="h2">Reproductive screening and counseling</span><span class="headingEndMark"> — </span>If both parents have sickle cell trait, the risk of sickle cell trait in their child is 50 percent, and the risk of homozygous sickle cell disease is 25 percent  (<a class="graphic graphic_figure graphicRef123050" href="/d/graphic/123050.html" rel="external">figure 1</a>). Similar considerations apply if other hemoglobin beta locus (<em>HBB</em>) variants are present in one or both parents. </p><p>For carrier couples at risk for sickle cell disease in a fetus, prenatal diagnostic testing (chorionic villus sampling [CVS], amniocentesis) is available; this allows diagnosis of sickle cell disease after conception and facilitates counseling. Cell-free DNA (sampling fetal DNA from the maternal circulation) is being explored. The decision to perform invasive prenatal diagnostic testing requires early in-depth discussion with the family concerning the associated risks versus the benefits of obtaining a diagnosis.</p><p class="headingAnchor" id="H1582945968"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals with the sickle cell variant should inform their at-risk relatives about this family history and the role of genetic counseling and testing. </p><p class="bulletIndent1"><span class="glyph">●</span>First-degree relatives of an individual with sickle cell trait have a 50 percent chance of inheriting the variant  (<a class="graphic graphic_figure graphicRef123050" href="/d/graphic/123050.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All biological children of an individual with homozygous sickle cell disease (Hb SS) will inherit one copy of the sickle cell variant. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In both cases, the relative's risk of having sickle cell disease depends on the beta globin gene they inherit from the other parent.</p><p></p><p>Counseling (and testing, if appropriate) can be facilitated by a genetic counselor, hematologist, or other expert. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p class="headingAnchor" id="H2925519431"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H513726784"><span class="h2">UpToDate topics</span></p><p>Sickle cell trait and sickle cell disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Prenatal testing – (See  <a class="medical medical_review" href="/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis – (See  <a class="medical medical_review" href="/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders"</a> and  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Sickle cell trait – (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Other sickle cell syndromes – (See  <a class="medical medical_review" href="/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E"</a> and  <a class="medical medical_review" href="/d/html/7115.html" rel="external">"Overview of compound sickle cell syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Management – (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p></p><p>Genetics:</p><p class="bulletIndent1"><span class="glyph">●</span>Terminology – (See  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Counseling – (See  <a class="medical medical_review" href="/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Testing – (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p></p><p class="headingAnchor" id="H3610458512"><span class="h2">Other sources of information</span></p><p class="bulletIndent1"><span class="glyph">●</span>American Society of Hematology (ASH) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hematology.org%2Feducation%2Fclinicians%2Fclinical-priorities%2Fscd-resources-for-clinicians&amp;token=tJlQVPRZbcms8qVc2Xs0s6nQu47ViFZCL0%2BEp66mSGQGAyfW4y%2BQIJMVy876ivtwB4Ja7mmWeUbE1vY4cTppMncDQnxL7ZGexJLcVWleMvpG87Mph0vGFDfVJxtVErx%2F&amp;TOPIC_ID=121893" target="_blank">Resources for clinicians</a> [<a href="#rid6">6</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Centers for Disease Control (CDC) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fncbddd%2Fsicklecell%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLIIcrAhco4uPEs6rZsJS2uLGDzw0%2Fd2yayrPdLSqON%2FQEeI9eRjTLtIh2IIVrCduDw%3D%3D&amp;TOPIC_ID=121893" target="_blank">website</a> [<a href="#rid7">7</a>]</p><p></p><p class="headingAnchor" id="H3316821475"><span class="h2">Locating a genetics expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=121893" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=121893" target="_blank">ACMG</a>)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Pecker LH, Naik RP. The current state of sickle cell trait: implications for reproductive and genetic counseling. Blood 2018; 132:2331.</a></li><li><a class="nounderline abstract_t">Naik RP, Smith-Whitley K, Hassell KL, et al. Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review. Ann Intern Med 2018; 169:619.</a></li><li><a class="nounderline abstract_t">Kark JA, Posey DM, Schumacher HR, Ruehle CJ. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med 1987; 317:781.</a></li><li><a class="nounderline abstract_t">Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.</a></li><li class="breakAll">https://www.hematology.org/education/clinicians/clinical-priorities/scd-resources-for-clinicians (Accessed on March 30, 2021).</li><li class="breakAll">https://www.cdc.gov/ncbddd/sicklecell/index.html (Accessed on October 02, 2019).</li></ol></div><div id="topicVersionRevision">Topic 121893 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30487130" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The current state of sickle cell trait: implications for reproductive and genetic counseling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383109" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3627196" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sickle-cell trait as a risk factor for sudden death in physical training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
